Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, announced his intention to retire, effective October 2, 2026. To streamline the operating model, the BioPharma Systems segment will now report directly to Chairman, CEO and President Thomas E. Polen. Becton, Dickinson and Company is a global medical technology company providing healthcare technologies, services, and solutions.

Becton, Dickinson and Company has resumed shipments of ChloraPrep in the U.S. following the completion of additional final release testing. The company reported that all testing results were acceptable and no patient safety signals have been identified.

Becton, Dickinson and Company's subsidiary issued €600 million in 3.855% notes due 2033 to refinance existing debt. The proceeds will be used to fully repay the company's 1.208% notes maturing in June 2026, with any remaining funds directed toward general corporate purposes. This transaction allows the company to manage its liquidity by extending its debt maturity profile.

Becton, Dickinson and Company has entered into an agreement to issue €600 million in 3.855% Euro Notes due 2033. The company intends to use the net proceeds to repay its existing 1.208% Euro Notes maturing in June 2026. This transaction allows the company to refinance near-term debt obligations and manage its long-term maturity profile.

Becton, Dickinson and Company has announced its financial results for the second fiscal quarter ending March 31, 2026. This release is a critical update for investors to evaluate the company's recent operational performance and fiscal trajectory.